We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
Read MoreHide Full Article
BioVie Inc. (BIVI - Free Report) announced a positive analysis of top-line efficacy data from its phase III study of its investigational candidate, NE3107, for the treatment of mild-to-moderate Alzheimer’s disease (AD).
Despite the encouraging results, BioVie’s stock plunged 60.7% in the last trading session, primarily due to investors’ skepticism regarding the results. Per the company, there were significant study conduct violations and protocol deviations.
NE3107 is an oral, small molecule, blood-brain permeable anti-inflammatory insulin sensitizer with a novel mechanism of action.
Per the data readout, the advantage of treating AD patients with NE3107 compared with placebo in the late-stage study demonstrated a benefit equal to or greater than that offered by currently approved monoclonal antibodies in the treatment of AD, without the associated safety concerns.
Furthermore, BioVie reported that NE3107-treated patients experienced an age deceleration advantage by 4.66 months to a year compared with placebo, as measured by epigenetics/DNA methylation Skin Blood Clock. Age deceleration is the difference between the patient’s biological age as measured by the Horvath DNA methylation Skin Blood clock and the actual chronological age.
Management believes NE3107 to be the first drug candidate to demonstrate this impact on DNA methylation and the aging process in a clinical study.
Year to date, shares of BioVie have nosedived 74.8% compared with the industry’s 12.8% fall.
Image Source: Zacks Investment Research
The phase III study of NE3107, initiated during the COVID-19 pandemic, enrolled a total of 439 AD patients. After completion of the study, BIVI observed significant deviation from protocol and good clinical practice violations in several study sites.
Based on this development, the company decided to exclude all patients treated with the candidate in these study sites from the analysis of study efficacy data. The excluded patients were then referred to an investigative body of the FDA for further action.
After accounting for the exclusions, 81 patients remained in the company’s modified intent to treat population, 57 of whom received treatment according to protocol. These 57 patients in the per-protocol population included those who went on to complete the study and were verified to take the study drug from pharmacokinetic data. The top-line efficacy results were upon analysis of data observed from these 57 per-protocol patients.
BioVie also reported that due to the exclusions made from the initial patient population, the primary efficacy endpoint of the study missed achieving statistical significance. This is expected to have contributed to the massive drop in the stock price.
The company intends to utilize the adaptive feature of the phase III study design to continue enrolling patients to reach statistical significance for registrational purposes.
Currently, BioVie is gearing up to discuss its findings regarding the magnitude of NE3107’s therapeutic impact with its potential partners.
Some other top-ranked stocks worth mentioning are Puma Biotechnology, Inc. (PBYI - Free Report) , ADMA Biologics (ADMA - Free Report) and Agenus (AGEN - Free Report) . While PBYI sports a Zacks Rank #1 (Strong Buy), ADMA and AGEN carry a Zacks Rank #2 each at present.
In the past 30 days, the Zacks Consensus Estimate for Puma Biotech’s 2023 earnings per share has increased from 67 cents to 73 cents. During the same time frame, the estimate for Puma Biotech’s 2024 earnings per share has increased from 56 cents to 62 cents. Year to date, shares of PBYI have lost 8.3%.
PBYI’s earnings beat estimates in three of the last four quarters while missing on one occasion, delivering a four-quarter average earnings surprise of 76.55%.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2023 loss per share has narrowed from 6 cents to 3 cents. The estimate for ADMA Biologics’ 2024 earnings per share is pegged at 16 cents. Year to date, shares of ADMA have lost 3.9%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 63.57%.
In the past 30 days, the Zacks Consensus Estimate for Agenus’ 2023 loss per share has narrowed from 77 cents to 63 cents. During the same time frame, the estimate for Agenus’ 2024 loss per share has narrowed from 70 cents to 45 cents. Year to date, shares of AGEN have plunged 70.8%.
AGEN beat estimates in one of the trailing four quarters, matching in one and missing the mark on the other two occasions, delivering an average earnings surprise of 0.49%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
BioVie Inc. (BIVI - Free Report) announced a positive analysis of top-line efficacy data from its phase III study of its investigational candidate, NE3107, for the treatment of mild-to-moderate Alzheimer’s disease (AD).
Despite the encouraging results, BioVie’s stock plunged 60.7% in the last trading session, primarily due to investors’ skepticism regarding the results. Per the company, there were significant study conduct violations and protocol deviations.
NE3107 is an oral, small molecule, blood-brain permeable anti-inflammatory insulin sensitizer with a novel mechanism of action.
Per the data readout, the advantage of treating AD patients with NE3107 compared with placebo in the late-stage study demonstrated a benefit equal to or greater than that offered by currently approved monoclonal antibodies in the treatment of AD, without the associated safety concerns.
Furthermore, BioVie reported that NE3107-treated patients experienced an age deceleration advantage by 4.66 months to a year compared with placebo, as measured by epigenetics/DNA methylation Skin Blood Clock. Age deceleration is the difference between the patient’s biological age as measured by the Horvath DNA methylation Skin Blood clock and the actual chronological age.
Management believes NE3107 to be the first drug candidate to demonstrate this impact on DNA methylation and the aging process in a clinical study.
Year to date, shares of BioVie have nosedived 74.8% compared with the industry’s 12.8% fall.
Image Source: Zacks Investment Research
The phase III study of NE3107, initiated during the COVID-19 pandemic, enrolled a total of 439 AD patients. After completion of the study, BIVI observed significant deviation from protocol and good clinical practice violations in several study sites.
Based on this development, the company decided to exclude all patients treated with the candidate in these study sites from the analysis of study efficacy data. The excluded patients were then referred to an investigative body of the FDA for further action.
After accounting for the exclusions, 81 patients remained in the company’s modified intent to treat population, 57 of whom received treatment according to protocol. These 57 patients in the per-protocol population included those who went on to complete the study and were verified to take the study drug from pharmacokinetic data. The top-line efficacy results were upon analysis of data observed from these 57 per-protocol patients.
BioVie also reported that due to the exclusions made from the initial patient population, the primary efficacy endpoint of the study missed achieving statistical significance. This is expected to have contributed to the massive drop in the stock price.
The company intends to utilize the adaptive feature of the phase III study design to continue enrolling patients to reach statistical significance for registrational purposes.
Currently, BioVie is gearing up to discuss its findings regarding the magnitude of NE3107’s therapeutic impact with its potential partners.
BioVie Inc. Price and Consensus
BioVie Inc. price-consensus-chart | BioVie Inc. Quote
Zacks Rank and Other Stocks to Consider
BioVie currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks worth mentioning are Puma Biotechnology, Inc. (PBYI - Free Report) , ADMA Biologics (ADMA - Free Report) and Agenus (AGEN - Free Report) . While PBYI sports a Zacks Rank #1 (Strong Buy), ADMA and AGEN carry a Zacks Rank #2 each at present.
You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for Puma Biotech’s 2023 earnings per share has increased from 67 cents to 73 cents. During the same time frame, the estimate for Puma Biotech’s 2024 earnings per share has increased from 56 cents to 62 cents. Year to date, shares of PBYI have lost 8.3%.
PBYI’s earnings beat estimates in three of the last four quarters while missing on one occasion, delivering a four-quarter average earnings surprise of 76.55%.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2023 loss per share has narrowed from 6 cents to 3 cents. The estimate for ADMA Biologics’ 2024 earnings per share is pegged at 16 cents. Year to date, shares of ADMA have lost 3.9%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 63.57%.
In the past 30 days, the Zacks Consensus Estimate for Agenus’ 2023 loss per share has narrowed from 77 cents to 63 cents. During the same time frame, the estimate for Agenus’ 2024 loss per share has narrowed from 70 cents to 45 cents. Year to date, shares of AGEN have plunged 70.8%.
AGEN beat estimates in one of the trailing four quarters, matching in one and missing the mark on the other two occasions, delivering an average earnings surprise of 0.49%.